Ilya Rachman
Patrimonio netto: 16 M $ in data 31/08/2026
Patrimonio netto: 16 M $ in data 31/08/2026
Ilya Rachman is the founder of Immix Biopharma, Inc., founded in 2012, holding the title of Chairman & Chief Executive Officer.
Dr. Rachman currently holds the positions of Chief Executive Officer, Secretary, and Director at Nexcella, Inc. Education history includes an MBA from the University of California, Los Angeles; graduate and doctorate degrees from the University of Illinois; and an undergraduate degree from the University of Iowa.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 22/05/2026 | 1.141.683 ( 1,6% ) | 16 M $ | 31/08/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| IMMIX BIOPHARMA, INC. | Amministratore Delegato | 01/01/2012 |
Nexcella, Inc.
Nexcella, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops cell therapies for AL amyloidosis and immune-mediated diseases | Amministratore Delegato | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 5 |
|---|---|
University of California, Los Angeles
University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois
University of Illinois Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Iowa
University of Iowa Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immix Biopharma, Inc.
Immix Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops therapies for cancer patients | Health Technology |
Nexcella, Inc.
Nexcella, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops cell therapies for AL amyloidosis and immune-mediated diseases | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale